Louisiana State Employees Retirement System Invests $223,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Louisiana State Employees Retirement System bought a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 11,700 shares of the company’s stock, valued at approximately $223,000.

Several other institutional investors have also recently added to or reduced their stakes in ITOS. BlackRock Inc. raised its holdings in iTeos Therapeutics by 106.5% during the first quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock worth $107,203,000 after purchasing an additional 1,718,085 shares in the last quarter. State Street Corp lifted its position in iTeos Therapeutics by 124.3% in the first quarter. State Street Corp now owns 1,711,891 shares of the company’s stock valued at $55,089,000 after acquiring an additional 948,540 shares during the last quarter. Vanguard Group Inc. boosted its stake in iTeos Therapeutics by 39.1% in the first quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company’s stock valued at $47,499,000 after acquiring an additional 415,232 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 146.7% during the second quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company’s stock worth $11,522,000 after purchasing an additional 332,625 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of iTeos Therapeutics by 276.9% in the 2nd quarter. AQR Capital Management LLC now owns 445,110 shares of the company’s stock valued at $9,169,000 after purchasing an additional 327,025 shares during the last quarter.

iTeos Therapeutics Stock Down 1.3 %

NASDAQ:ITOS opened at $18.95 on Friday. The company has a market capitalization of $674.15 million, a PE ratio of 2.75 and a beta of 1.38. iTeos Therapeutics, Inc. has a 52-week low of $16.21 and a 52-week high of $41.00. The stock’s 50 day moving average price is $19.70 and its 200 day moving average price is $21.09.

iTeos Therapeutics (NASDAQ:ITOSGet Rating) last announced its earnings results on Thursday, November 10th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). The business had revenue of $19.49 million for the quarter, compared to analysts’ expectations of $42.05 million. iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. As a group, sell-side analysts anticipate that iTeos Therapeutics, Inc. will post 2.85 EPS for the current fiscal year.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Further Reading

Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating).

Institutional Ownership by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.